Recombinant EGFR (Cetuximab Biosimilar) antibody

Catalog No. ABIN7200654

The Mouse Monoclonal anti-EGFR (Cetuximab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect EGFR (Cetuximab Biosimilar) in samples from Human.

Quick Overview for Recombinant EGFR (Cetuximab Biosimilar) antibody (ABIN7200654)

Target: EGFR (Cetuximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EGFR (Cetuximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Clone: C225

Product Details anti-EGFR (Cetuximab Biosimilar) Antibody

Purpose: Cetuximab Biosimilar, Human EGFR Monoclonal Antibody

Specificity: The monoclonal antibody cetuximab biosimilar specifically binds to the human EGFR.

Characteristics: Recombinant Chimeric IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody cetuximab biosimilar was produced in the cetuximab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cetuximab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for EGFR (Cetuximab Biosimilar)

Target: EGFR (Cetuximab Biosimilar)

Target Type: Biosimilar

Background: Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.

Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.

There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.